Eric Abadie resigns as chair of the CHMP
pharmafile | April 5, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | CHMP, Eric Abadie
Dr Eric Abadie has told the European Medicines Agency that he is resigning as chair of the Committee for Medicinal Products for Human Use (CHMP).
The CHMP is responsible for preparing the Agency’s opinions on all questions concerning medicines for human use.
The Agency’s executive director Guido Rasi has accepted his resignation with immediate effect.
Dr Tomas Salmonson, vice-chair of the CHMP, will lead the Committee in the meantime to ensure continuity of operations.
Related Content

Bristol Myers Squibb receives positive CHMP opinion for Opdivo treatment
Bristol Myers Squibb (BMS) has received a positive opinion from the Committee for Medicinal Products …

Eplontersen recommended for EU approval by CHMP for treatment of hereditary transthyretin-mediated amyloidosis
Wainzua (eplotersen), produced by AstraZeneca and Ionis, has been recommended for approval in the European …

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI in combination with MEKTOVI for the treatment of adult patients with advanced non-small cell lung cancer NSCLC) with a BRAFV600E mutation
Pierre Fabre Laboratories has announced a positive opinion from the European Medical Association’s (EMA) Committee …






